Clinical Trials Logo

Filter by:
NCT ID: NCT02161835 Completed - Congenital Myotonia Clinical Trials

Relations Between Myotonia and Fitness

Start date: April 2014
Phase: N/A
Study type: Interventional

Investigators aimed to investigate whether training can increase fitness levels in patients with myotonia, and thereby reduce the symptom of myotonia.

NCT ID: NCT02161666 Completed - Obesity Clinical Trials

Effect of Gastric Bypass Surgery on Pancreatic Islet and Incretin Function - Follow-up Study

Start date: February 2014
Phase: N/A
Study type: Observational

To examine pancreatic islet function and incretin function during intravenous and oral stimulation >2 years after gastric bypass surgery in patients with normal glucose tolerance. We hypothesize that islet cell and incretin function is enhanced in response to oral, but not intravenous, stimulation - i.e. incretin released from the gut in response to oral stimulation play a key role for the enhanced islet function after gastric bypass surgery.

NCT ID: NCT02160899 Completed - Clinical trials for Elevated Lipoprotein(a)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)

Start date: June 2014
Phase: Phase 2
Study type: Interventional

The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS-APO(a)Rx given to participants with high lipoprotein(a) for 12 weeks.

NCT ID: NCT02160457 Completed - Cerebral Palsy Clinical Trials

Gait Analysis and Interdisciplinary Interventions for Children With Cerebral Palsy

CPinMotion
Start date: August 6, 2014
Phase: N/A
Study type: Interventional

The aim of this study is to test the hypothesis, that improvements in gait pattern following individually tailored interventions guided by instrumented 3-dimensional gait analysis are superior to those used in 'care as usual'.

NCT ID: NCT02160145 Completed - Clinical trials for Chronic Kidney Disease

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Start date: May 2014
Phase: Phase 3
Study type: Interventional

The purpose of the study is to determine whether tolvaptan is effective and safe for the treatment of late-stage chronic kidney disease due to autosomal dominant polycystic kidney disease (ADPKD)

NCT ID: NCT02159963 Completed - Clinical trials for FSHD - Facioscapulohumeral Muscular Dystrophy

High Intensity Training in Patients With Facioscapulohumeral Muscular Dystrophy

HIT-FSHD
Start date: June 2014
Phase: N/A
Study type: Interventional

The investigators aim to investigate the effect of high-intensity training in patients with facioscapulohumeral muscular dystrophy. Can patients benefit from this type of exercise without muscle damage.

NCT ID: NCT02159612 Completed - Clinical trials for FSHD - Facioscapulohumeral Muscular Dystrophy

1 Year MRI Followup in Facioscapulohumeral Muscular Dystrophy

FSHD
Start date: May 2014
Phase: N/A
Study type: Observational

An investigation of disease progression in adult danish patients with facioscapulohumeral muscular dystrophy. The disease progression is followed for a year with two test-days, including functional muscle tests and a MRI scan of muscles in the back and legs.

NCT ID: NCT02159274 Completed - Breast Cancer Clinical Trials

Shoulder Disability and Late Symptoms Following Oncoplastic Breast Surgery

Start date: March 2014
Phase:
Study type: Observational [Patient Registry]

Breast cancer affects a large proportion of Danish women and late morbidity following breast cancer treatment including pain, reduced motility and force of the arm and shoulder, disturbed sensitivity, and lymph edema affects many patients. The risk for such late complications have previously been carefully described by us and others in patients operated by traditional methods, but the follow-up in most of these studies have been rather short , and long time follow-up results are not available. The impact of the new oncoplastic techniques that allows more women to have breast conserving surgery is not known yet. These operations are more extensive and therefore might be accompanied by more complications. The purpose of this study is to give answer to that question.The study includes three parts. First a questionnaire to patients who have breast conserving surgery performed in one of the three breast units in Central Region Denmark. It contains questions regarding arm morbidity, quality of life, comorbidity, and body image. The questionnaire should be filled in preoperatively and 18 months after surgery. The second part consists of an objective evaluation of shoulder and arm function and cosmesis before and after breast conserving surgery with and without oncoplastic techniques. This should be performed at baseline before surgery and 18 months later. The third part is a long time follow-up of patients after breast conserving surgery without oncoplastic techniques. This group of patients is recruited from three breast units in Central Region Denmark. It contains questions regarding arm morbidity, quality of life, comorbidity, and body image. The questionnaire should be filled in preoperatively and 18 months after surgery. The second part consists of an objective evaluation of shoulder and arm function and cosmesis before and after breast conserving surgery with and without oncoplastic techniques. This should be performed at baseline before surgery and 18 months later. The third part is a long time follow-up of patients after breast conserving surgery without oncoplastic techniques. This group of patients is recruited from the cohort in a previous study with 18 months follow-up following breast conserving surgery without oncoplastic technique.

NCT ID: NCT02159053 Completed - Clinical trials for Spondylitis, Ankylosing

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis

MEASURE4
Start date: May 18, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide 16-week efficacy, safety and tolerability data versus placebo to support the use of secukinumab 150 mg by subcutaneous (s.c.) self-administration with or without a loading regimen and maintenance dosing using pre-filled syringe (PFS) and to assess efficacy, safety and tolerability up to 2 years in subjects with active AS despite current or previous NSAID, non-biologic DMARD, or biologic anti-TNFα therapy.

NCT ID: NCT02158221 Completed - Clinical trials for Migraine Without Aura

PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load

Start date: June 2014
Phase: N/A
Study type: Interventional

The investigators hypothesized that migraine without patients with many genetic loci associated with migraine (high genetic load) would be more sensitive and get provoked more migraine attacks by PACAP compared to patients with few genetic loci associated with migraine (low genetic load).